NeoGenomics (NEO) Reaches New 52-Week High at $20.01

NeoGenomics, Inc. (NASDAQ:NEO) shares reached a new 52-week high during trading on Thursday . The stock traded as high as $20.01 and last traded at $19.77, with a volume of 425228 shares. The stock had previously closed at $19.59.

Several research analysts recently commented on the stock. CIBC raised shares of NeoGenomics from a “neutral” rating to an “outperform” rating and reduced their price target for the stock from $18.00 to $15.00 in a research note on Tuesday. Zacks Investment Research raised shares of NeoGenomics from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research note on Tuesday, March 5th. BidaskClub raised shares of NeoGenomics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 20th. ValuEngine raised shares of NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 10th. Finally, Needham & Company LLC assumed coverage on shares of NeoGenomics in a research report on Thursday, January 3rd. They set a “buy” rating and a $14.00 target price on the stock. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. NeoGenomics presently has an average rating of “Buy” and a consensus price target of $18.82.

The company has a current ratio of 1.70, a quick ratio of 1.56 and a debt-to-equity ratio of 0.31. The stock has a market cap of $1.86 billion, a P/E ratio of 152.08 and a beta of 0.94.



NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, February 19th. The medical research company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $76.50 million for the quarter, compared to the consensus estimate of $71.29 million. NeoGenomics had a net margin of 0.95% and a return on equity of 2.25%. The company’s revenue for the quarter was up 24.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.05 EPS. Analysts anticipate that NeoGenomics, Inc. will post 0.18 earnings per share for the current year.

In other news, VP Jennifer Balliet sold 30,000 shares of the firm’s stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $19.57, for a total value of $587,100.00. Following the sale, the vice president now directly owns 40,000 shares in the company, valued at approximately $782,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Steven C. Jones sold 14,621 shares of the firm’s stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $19.24, for a total transaction of $281,308.04. Following the completion of the sale, the executive vice president now owns 241,815 shares in the company, valued at $4,652,520.60. The disclosure for this sale can be found here. Insiders have sold a total of 11,098,669 shares of company stock worth $135,041,236 in the last three months. Insiders own 12.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Howland Capital Management LLC boosted its holdings in shares of NeoGenomics by 2.9% in the 4th quarter. Howland Capital Management LLC now owns 31,337 shares of the medical research company’s stock valued at $395,000 after buying an additional 888 shares in the last quarter. Marshall Wace North America L.P. boosted its holdings in shares of NeoGenomics by 0.4% in the 3rd quarter. Marshall Wace North America L.P. now owns 220,059 shares of the medical research company’s stock valued at $3,378,000 after buying an additional 934 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of NeoGenomics by 10.0% in the 3rd quarter. Legal & General Group Plc now owns 10,559 shares of the medical research company’s stock valued at $162,000 after buying an additional 963 shares in the last quarter. Ruggie Capital Group boosted its holdings in shares of NeoGenomics by 74.1% in the 4th quarter. Ruggie Capital Group now owns 2,350 shares of the medical research company’s stock valued at $30,000 after buying an additional 1,000 shares in the last quarter. Finally, Suntrust Banks Inc. boosted its holdings in shares of NeoGenomics by 2.6% in the 4th quarter. Suntrust Banks Inc. now owns 39,959 shares of the medical research company’s stock valued at $504,000 after buying an additional 1,028 shares in the last quarter. Institutional investors and hedge funds own 78.17% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://dakotafinancialnews.com/2019/03/15/neogenomics-neo-reaches-new-52-week-high-at-20-01.html.

About NeoGenomics (NASDAQ:NEO)

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Featured Story: How is a Moving Average Calculated?

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.